Bellevue Group AG Has $146.70 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

Bellevue Group AG increased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 0.1% during the 1st quarter, Holdings Channel reports. The institutional investor owned 9,965,862 shares of the biopharmaceutical company’s stock after buying an additional 12,549 shares during the period. MacroGenics makes up 2.2% of Bellevue Group AG’s holdings, making the stock its 13th biggest holding. Bellevue Group AG owned 0.16% of MacroGenics worth $146,697,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in shares of MacroGenics by 3.0% during the third quarter. Wellington Management Group LLP now owns 248,520 shares of the biopharmaceutical company’s stock worth $1,158,000 after purchasing an additional 7,215 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of MacroGenics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,414,924 shares of the biopharmaceutical company’s stock valued at $20,574,000 after buying an additional 36,396 shares during the period. SG Americas Securities LLC increased its stake in shares of MacroGenics by 36.9% in the 4th quarter. SG Americas Securities LLC now owns 28,589 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 7,712 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of MacroGenics by 349.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,174 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 5,577 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of MacroGenics by 7.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,337 shares of the biopharmaceutical company’s stock valued at $475,000 after acquiring an additional 3,319 shares during the period. Institutional investors own 96.89% of the company’s stock.

MacroGenics Price Performance

Shares of MGNX traded up $0.05 during mid-day trading on Friday, hitting $5.55. 631,316 shares of the company’s stock were exchanged, compared to its average volume of 926,417. The company has a 50-day simple moving average of $4.56 and a 200 day simple moving average of $11.34. The company has a market cap of $347.60 million, a PE ratio of -14.23 and a beta of 2.08. MacroGenics, Inc. has a 52 week low of $3.14 and a 52 week high of $21.88.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.17). MacroGenics had a negative net margin of 53.60% and a negative return on equity of 98.01%. The company had revenue of $9.10 million for the quarter, compared to analyst estimates of $13.63 million. On average, analysts anticipate that MacroGenics, Inc. will post -3.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of MacroGenics from $16.00 to $4.00 and set a “neutral” rating for the company in a research report on Monday, May 13th. Stifel Nicolaus cut MacroGenics from a “buy” rating to a “hold” rating and lowered their price target for the company from $29.00 to $7.00 in a research note on Friday, May 10th. BMO Capital Markets cut shares of MacroGenics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $24.00 to $8.00 in a report on Friday, May 10th. JMP Securities cut their target price on shares of MacroGenics from $22.00 to $16.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Finally, TD Cowen downgraded MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, MacroGenics currently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.